ASND Stock Analysis: Buy, Sell, or Hold?
ASND - Ascendis Pharma A/S American Depositary Shares
$264.37
-6.08 (-2.25%)
▼
5d:
-1.33%
30d:
+26.02%
90d:
+10.49%
BUY
MODERATE Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 06, 2026
23d
Get Alerted When ASND Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ASND this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ASND shows positive signals but monitor for confirmation. Market pricing in 2.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ASND shows positive signals but monitor for confirmation. Market pricing in 2.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$174.33
Based on -5.8% avg growth
INTRINSIC VALUE TODAY
$108.25
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ASND is currently trading at $264.37, which is considered slightly high relative to its 30-day fair value range of $219.17 to $267.77. The stock's valuation (Forward PE: 28.5) is in line with its historical norms (31.1). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ASND is in a uptrend. The price is currently testing key support at $256.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASND has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ASND is in a uptrend. The price is currently testing key support at $256.73. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: ASND has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$219.17 -
$267.77
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($297.24)
Trading Range Analysis
30-Day Trading Range
$219.17 -
$267.77
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$256.73
Resistance Level
$282.15
Current Trend
Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.46
Wall Street Target
$297.24
(+9.9%)
Revenue Growth (YoY)
144.3%
Profit Margin
57.3%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
28.5 vs 31.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$262.61
(-3%)
2-Year Target
$254.99
(-6%)
3-Year Target
$247.60
(-9%)
3-Yr Target (if PE normalizes)
(PE: 28→31)
$270.57
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.5, Growth: -15.5%)
$197.16
(+-27%)
Base:
(SPY PE: 21.8, Growth: -15.5%)
$150.89
(-44%)
Bear:
(PE: 18.5, Growth: -15.5%)
$128.25
(-53%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (32x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Trailing PE: 32.14 | Current EPS (TTM): $8.57
Bull Case
$335.96
(+24%)
Analyst growth 10.9%, PE expands to 35.4
Base Case
$305.42
(+13%)
Market implied 10.9%, PE stable at 32.1
Bear Case
$187.29
(-31%)
Severe decline -20.0%, PE contracts to 27.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 28.5 to 31.1
Stabilization Target:
$295.54
(+9.3%)
PE Expansion Potential:
+9.3%
Share & Embed Analysis
Last updated: July 13, 2026 10:24 AM ET
Data refreshes hourly during market hours. Next update: 11:24 AM
Data refreshes hourly during market hours. Next update: 11:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ASND showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 57 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
